[Among patients with acute coronary syndrome who underwent percutaneous coronary intervention with contemporary stents and had no ischemic or hemorrhagic events during 1 month on dual antiplatelet therapy, does treatment with ticagrelor alone between the 1st and 12th month reduce the risk of clinically relevant bleeding while remaining effective in preventing vascular complications compared to ticagrelor combined with aspirin?]